Related Experiment Video
Updated: Jul 13, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
Published on: October 31, 2025
[Clinical and evolutionary aspects of polymyosite in internal medicine]
Introduction:
Polymyositis is a chronic inflammatory disease possibly responsable of various systemic manifestations.
Patients And Methods:
Reported is a retrospective done on polymyositis i n internal medecine department in patients from march 1997 to april 2002.
Results:
Eleven cases were collected from a total of 6739 admissions giving a prevalence of 0.16%. Sex ratio was 1.2(F/H) with a mean age of 33 years. The most frequent clinical presentation was the muscle signs. It was dominated by the functionnal disability (90.9%), myalgia (81.8%) and dysphagia (36.3%). Systemic manifestations of polymyositis interested articulary, bronchopulmonary, cardiac and neurological areas. Association of polymyositis and other sytemic disease has been found in one patient, who presented also a rhumatoid arthritis. First step treatment was corticotherapy for all patients. Immunosuppressor with azathioprine have been introduced in 2 patients who presented an associated interstitial nulmonary disease. On this treatment we observed 4 cases of total remission, 3 cases of partial remission, 2 death occured and 2 patients have been lost from clinical follow up.
Conclusion:
The long term follow of these chronic disease is a major problem in developping countries. Most of the patients live far from hospital centers and don't have possibility to do complementary exams so as to buy regulary the drugs.
Insights
Polymyositis, a chronic inflammatory disease, affects patients with muscle weakness and systemic symptoms. Long-term management presents challenges, especially in developing nations, impacting patient outcomes and treatment adherence.
Area of Science:
- Rheumatology
- Neurology
- Internal Medicine
Context:
- Polymyositis is a rare chronic inflammatory myopathy.
- Systemic manifestations can significantly impact patient health.
- Understanding prevalence and clinical features is crucial for diagnosis and management.
Purpose:
- To determine the prevalence of polymyositis.
- To describe the clinical presentation and systemic manifestations.
- To evaluate treatment outcomes and challenges in patient follow-up.
Summary:
- A retrospective study identified 11 polymyositis cases over 5 years, with a prevalence of 0.16%.
- The primary symptoms included functional disability, myalgia, and dysphagia, with various systemic involvements.
- Corticosteroids were the initial treatment, with azathioprine used for pulmonary complications, showing mixed remission and mortality rates.
Impact:
- Highlights the importance of recognizing polymyositis' diverse clinical spectrum.
- Underscores the difficulties in managing chronic diseases in resource-limited settings.
- Informs clinical practice regarding treatment strategies and long-term patient care for polymyositis.
Related Concept Videos
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis I: Introduction
Myocarditis III: Medical Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Inflammatory Bowel Disease IV: Clinical Manifestations
Pericarditis II: Clinical Features and Diagnostic Tests